AIGR TreeGrafter Function-Inference Stress Test

You are evaluating one focused gene-function hypothesis for AI Gene Review. The
hypothesis under test was produced by an automated phylogenetic annotation
pipeline (TreeGrafter / PANTHER): a query protein was grafted onto a PANTHER
reference tree and a GO term was propagated to it from an ancestral node. Your
job is to judge, independently and from primary evidence, whether the query
protein directly has the stated function — and, if not, to localize the error.

This is not a general gene overview. Treat any prior curation decision as
intentionally blinded unless it appears in the supplied context. Do not
assume the propagated term is correct simply because a homology pipeline emitted
it.

Target Gene

• Organism code: DOROP
• Taxon: Doryteuthis opalescens (NCBITaxon:1051066)
• Gene directory: ADAR2
• Gene symbol: ADAR2
• UniProt accession: C1JAR3

Focus

• Focus type: function_assignment
• Hypothesis slug: function-hypothesis-go-0008251
• Source file: genes/DOROP/ADAR2/ADAR2-ai-review.yaml
• Source selector: existing_annotations[10].function_hypothesis

Seed Hypothesis (propagated by TreeGrafter/PANTHER)

ADAR2 has tRNA-specific adenosine deaminase activity (GO:0008251).

Term and Decision Context

• Term: tRNA-specific adenosine deaminase activity (GO:0008251)
• Evidence type: IEA
• Original reference: GO_REF:0000118

Reference Context

• GO_REF:0000118
• PMID:37342458
• PMID:19390115

Source Context YAML

term:
  id: GO:0008251
  label: tRNA-specific adenosine deaminase activity
evidence_type: IEA
original_reference_id: GO_REF:0000118

Research Objective

Decide whether ADAR2 directly has the stated function. Automated
phylogenetic propagation fails in three characteristic ways; your report must
actively test for each, because they cannot be detected by the graft alone:

1. Granularity / family-vs-subfamily. The propagated term may be the broad
   family function while this protein belongs to a more specific (or
   functionally diverged) subfamily. Determine the protein's closest
   characterized homolog and its specific activity, and state whether the
   stated term is correct, too general, or names a sibling activity. (Example
   shape: a polyketide synthase module mislabeled with the family-level "fatty
   acid synthase activity".)
2. Pseudo-enzyme / loss of activity. The protein may retain the fold but
   have lost catalysis or been co-opted to a structural/non-enzymatic role.
   Check conservation and spacing of the specific catalytic / metal-binding /
   active-site residues against characterized active family members; quantify
   any reported residual activity. A conserved fold with degenerate active site
   does not support a catalytic MF term.
3. Within-superfamily mis-placement. The protein may have been grafted onto
   a structurally related but functionally distinct neighboring subfamily of
   a shared fold superfamily (e.g. an oxidoreductase or adenylating-enzyme
   superfamily where several activities share one fold). Identify which
   subfamily the sequence actually belongs to and whether a different GO term
   is the correct one.

Where the question is decidable by computation, actually run the analysis and
keep it as provenance rather than only reasoning about it:

• Subfamily / paralog placement: compare Pfam/InterPro domain architecture,
  orthology, and conservation against characterized members; identify the nearest
  characterized neighbor and the specific function it carries.
• Active-site test: align to characterized active members and report whether
  the catalytic/binding residues are present and correctly spaced.
• Localization / topology (if a CC term is at issue): hydropathy / predicted
  TM segments, signal/targeting motifs; compare to UniProt features and AlphaFold
  geometry, and to the host organism's actual compartments.

Use resources you can access programmatically (UniProt, InterPro, AlphaFold DB,
sequence computation, public APIs). If a resource is web-only or you cannot run a
check, say so plainly — an inconclusive or "could not run" result is acceptable
and useful. Never fabricate a result. Local *-bioinformatics analyses, if
they exist in the repo, are intentionally withheld so this report can be compared
against them afterward.

Required Output

Executive Judgment

Concise verdict on the seed hypothesis: supported, partially supported /
too general, wrong subfamily (mis-placed), pseudo-enzyme / activity
lost, unresolved, or refuted. Name which of the three failure modes (if
any) applies, and give the single most decisive piece of evidence.

Independent Family/Function Assignment

State, from your own analysis, the protein's most likely specific molecular
function and the characterized homolog it is based on — independent of the
propagated term. Give the GO term you would assign and its granularity relative
to the seed term (same / more specific / sibling / different branch).

Evidence Matrix

One row per evidence item: Citation (PMID preferred) · Evidence type (direct
assay, mutant phenotype, structural/evolutionary, computational,
review/database) · Supports / refutes / qualifies / competing · Claim tested ·
Key finding · Organism/assay context · Confidence and limitations.

Active-Site / Placement Analysis

Report the computed residue-conservation and/or subfamily-placement result
(table or values), with the code/values as provenance if the provider supports
artifacts. State explicitly whether catalytic residues are intact.

GO Curation Implications

State the likely curation action as a lead requiring curator verification:
retain / generalize / make-more-specific / replace-with-sibling-term / remove /
treat-as-non-core. Avoid "protein binding" as a final recommendation.

Conflicts, Knowledge Gaps, Discriminating Tests

Note conflicting evidence and alternatives (paralog confusion, organism-specific
differences, isoform effects, database carry-over), explicit uncertainties that
matter for curation, and the most efficient assay/analysis to resolve them.

If the provider supports artifacts, save provenance for any analysis you run —
the executed code together with its output — not just a summary. Do not
synthesize a figure implying an analysis you did not run.

AIGR TreeGrafter Function-Inference Stress Test Report: ADAR2 (C1JAR3) from Doryteuthis opalescens

Executive Judgment

Verdict: REFUTED — Wrong subfamily (mis-placed); Failure mode #3: Within-superfamily mis-placement.

The seed hypothesis that ADAR2 (UniProt C1JAR3) from Doryteuthis opalescens has "tRNA-specific adenosine deaminase activity" (GO:0008251) is refuted. The protein is a bona fide member of the ADAR (Adenosine Deaminase Acting on RNA) family, which acts on double-stranded RNA (dsRNA) substrates — not tRNA. The GO term GO:0008251 describes the activity of the ADAT (Adenosine Deaminase Acting on tRNA) family, a structurally related but functionally distinct sibling subfamily within the adenosine deaminase superfamily. The TreeGrafter/PANTHER pipeline propagated a GO term from an ancestral node that encompasses both ADAR and ADAT lineages, failing to distinguish between these two sibling activities that diverged early in eukaryotic evolution.

Single most decisive piece of evidence: Palavicini, O'Connell, and Rosenthal (2009, PMID:19390115) cloned this exact protein (sqADAR2b, GenBank FJ478451) from Loligo (Doryteuthis) opalescens and demonstrated that recombinant sqADAR2b is catalytically active on duplex RNA substrates, specifically editing K⁺ channel mRNAs (sqKv1.1A and sqKv1.2A) in vitro — not tRNA (palavicini2009anextradoublestranded pages 1-2, palavicini2009anextradoublestranded pages 6-7).

Independent Family/Function Assignment

Protein identity: C1JAR3 corresponds to sqADAR2b from Doryteuthis opalescens, the two-dsRBD splice variant of squid ADAR2 (palavicini2009anextradoublestranded pages 2-3, palavicini2009anextradoublestranded pages 1-2). Its closest characterized homolog is human ADAR2 (ADARB1), with ~61% deaminase domain identity and ~80% dsRBD identity (palavicini2009anextradoublestranded pages 2-3).

Most likely specific molecular function: Double-stranded RNA adenosine deaminase activity (GO:0003726, "adenosine deaminase activity, acting on RNA"). This enzyme catalyzes the hydrolytic deamination of adenosine to inosine within double-stranded regions of mRNA and other RNA substrates. In cephalopods, this activity is particularly important for recoding ion channel and transporter transcripts in the nervous system (rosenthal2015theemergingrole pages 5-6, palavicini2009anextradoublestranded pages 1-2).

Granularity relative to seed term: The correct GO term is a sibling of the seed term, not the same, more specific, or more general. Both GO:0003726 (dsRNA adenosine deaminase) and GO:0008251 (tRNA-specific adenosine deaminase) are children of adenosine deaminase activity within the GO hierarchy, but they describe fundamentally different substrate specificities — dsRNA versus tRNA.

Evidence Matrix

The following table summarizes the primary and review evidence relevant to the annotation of Doryteuthis opalescens ADAR2.

Table: This table summarizes primary and review evidence relevant to the annotation of Doryteuthis opalescens ADAR2. Across direct squid assays, structural comparisons, and recent reviews, the evidence consistently supports dsRNA-specific ADAR activity and refutes tRNA-specific adenosine deaminase activity.

Active-Site / Placement Analysis

The active-site and domain architecture comparison between squid ADAR2, human ADAR2, and ADAT enzymes is presented below:

Table: This table compares squid ADAR2 with human ADAR2 and ADAT/tRNA deaminases across architecture, catalytic residues, cofactor features, and substrate specificity. It highlights that squid ADAR2 is clearly a dsRNA-editing ADAR enzyme and that the propagated tRNA-specific GO term reflects a wrong-subfamily sibling-activity error.

Key findings from the active-site analysis:

1. Catalytic residues are intact and ADAR-type. The zinc-coordinating residues H458, C516, and C580 (sqADAR2a numbering) and the proton-shuttling glutamate E460 are all conserved in the squid protein, matching the ADAR2 catalytic signature HXE-X₅₅-PCX₆₅C (fisher2024structuralperspectiveson pages 5-6, palavicini2009anextradoublestranded pages 2-3).

2. IP6 binding is conserved. Twenty-two of 24 residues that coordinate inositol hexakisphosphate (IP6) in the human ADAR2 crystal structure are conserved in squid ADAR2 (palavicini2009anextradoublestranded pages 2-3). This IP6-binding cavity is a defining feature of ADAR-family deaminase domains and is absent in ADAT2/TadA enzymes (ashley2024adarfamilyproteins pages 7-8, fisher2024structuralperspectiveson pages 5-6).

3. Domain architecture is ADAR-type. sqADAR2b contains two dsRNA-binding domains (dsRBDs) and a C-terminal catalytic deaminase domain — the canonical ADAR2 architecture (palavicini2009anextradoublestranded pages 1-2, palavicini2009anextradoublestranded pages 6-7). ADAT enzymes lack dsRBDs entirely and instead form heterodimers (ADAT2/3) or homodimers (TadA) (ashley2024adarfamilyproteins pages 4-7, huebert2025frommetabolismto pages 20-22).

4. Catalytic activity is demonstrated on dsRNA. Recombinant sqADAR2a and sqADAR2b are both enzymatically active on duplex RNA, converting ~45-50% of available adenosines to inosines on non-specific substrates, and editing specific sites in K⁺ channel mRNAs at rates of 6-44% (palavicini2009anextradoublestranded pages 3-5, palavicini2009anextradoublestranded pages 6-7, palavicini2009anextradoublestranded pages 5-6).

5. No pseudo-enzyme characteristics. This is not a case of activity loss (failure mode #2). The protein has intact catalytic residues and demonstrated enzymatic activity.

GO Curation Implications

Recommended curation action: Replace with sibling term.

The current annotation of GO:0008251 ("tRNA-specific adenosine deaminase activity") should be removed and replaced with GO:0003726 ("adenosine deaminase activity, acting on RNA" / "double-stranded RNA adenosine deaminase activity"). This replacement is strongly supported by:

• Direct biochemical characterization of this exact protein on dsRNA substrates (palavicini2009anextradoublestranded pages 1-2, palavicini2009anextradoublestranded pages 6-7);
• Domain architecture diagnostic of ADAR, not ADAT subfamily (ashley2024adarfamilyproteins pages 4-7, palavicini2009anextradoublestranded pages 2-3);
• Conservation of the ADAR-specific IP6-binding cavity absent in ADAT enzymes (ashley2024adarfamilyproteins pages 7-8);
• Extensive literature placing cephalopod ADAR2 in the dsRNA-editing context (rosenthal2015theemergingrole pages 5-6, yablonovitch2017theevolutionand pages 12-13).

The evidence type for the replacement annotation could be upgraded from IEA to IDA (Inferred from Direct Assay) based on PMID:19390115, since the recombinant protein from this species was directly assayed.

Conflicts, Knowledge Gaps, and Discriminating Tests

Source of the annotation error

The most likely explanation for the mis-annotation is that the PANTHER reference tree groups ADAR and ADAT enzymes within a shared adenosine deaminase superfamily node, and the TreeGrafter algorithm propagated the ADAT-associated GO term GO:0008251 from an ancestral node to a branch that includes ADAR proteins. Both enzyme families share a homologous zinc-dependent deaminase domain (the cytidine deaminase superfamily fold) and catalyze the same chemical reaction (adenosine → inosine), but they differ fundamentally in substrate specificity (dsRNA vs. tRNA) and domain architecture (dsRBDs vs. heterodimer formation) (ashley2024adarfamilyproteins pages 4-7, budzko2023engineereddeaminasesas pages 2-3). ADARs evolved from ADAT ancestors through acquisition of dsRNA-binding domains via domain shuffling (budzko2023engineereddeaminasesas pages 2-3), but the substrate switch from tRNA to dsRNA represents a fundamental change in molecular function that should be captured at the GO annotation level.

No conflicting evidence

No evidence was found suggesting that any ADAR-family enzyme has tRNA-specific adenosine deaminase activity. The ADAR and ADAT families are consistently described as targeting distinct substrates across all reviewed sources (ashley2024adarfamilyproteins pages 7-8, ashley2024adarfamilyproteins pages 4-7, huebert2025frommetabolismto pages 20-22, budzko2023engineereddeaminasesas pages 2-3, zhang2024rnaeditingenzymes pages 1-2).

Knowledge gaps

1. No crystal structure of squid ADAR2. While human ADAR2 structures exist and squid ADAR2 residues map onto them well (fisher2024structuralperspectiveson pages 5-6, palavicini2009anextradoublestranded pages 2-3), a direct squid structure would confirm the predicted architecture. This gap does not affect the subfamily assignment.

2. tRNA editing formally not excluded by negative-result assay. Palavicini et al. tested dsRNA substrates but did not explicitly test tRNA substrates as negative controls (palavicini2009anextradoublestranded pages 1-2, palavicini2009anextradoublestranded pages 3-5). However, no ADAR-family enzyme has ever been shown to act on tRNA, and the domain architecture is diagnostic.

3. Isoform considerations. UniProt C1JAR3 likely corresponds to sqADAR2b (the two-dsRBD variant). The three-dsRBD variant sqADAR2a (GenBank FJ478450) is a splice variant of the same gene with higher editing activity (palavicini2009anextradoublestranded pages 6-7). Both variants are ADAR2 enzymes with identical substrate class.

Most efficient discriminating test

If formal confirmation were needed, an in vitro assay testing purified sqADAR2 on tRNA substrates (expected: no editing at position 34 or elsewhere on tRNA) versus dsRNA substrates (expected: robust A-to-I editing) would definitively resolve any residual ambiguity. However, the existing evidence is already sufficient to refute the tRNA-specific annotation with high confidence.

References

1. (palavicini2009anextradoublestranded pages 1-2): Juan Pablo Palavicini, Mary A. O'connell, and Joshua J.C. Rosenthal. An extra double-stranded rna binding domain confers high activity to a squid rna editing enzyme. RNA, 15 6:1208-18, Jun 2009. URL: https://doi.org/10.1261/rna.1471209, doi:10.1261/rna.1471209. This article has 49 citations and is from a domain leading peer-reviewed journal.

2. (palavicini2009anextradoublestranded pages 6-7): Juan Pablo Palavicini, Mary A. O'connell, and Joshua J.C. Rosenthal. An extra double-stranded rna binding domain confers high activity to a squid rna editing enzyme. RNA, 15 6:1208-18, Jun 2009. URL: https://doi.org/10.1261/rna.1471209, doi:10.1261/rna.1471209. This article has 49 citations and is from a domain leading peer-reviewed journal.

3. (palavicini2009anextradoublestranded pages 2-3): Juan Pablo Palavicini, Mary A. O'connell, and Joshua J.C. Rosenthal. An extra double-stranded rna binding domain confers high activity to a squid rna editing enzyme. RNA, 15 6:1208-18, Jun 2009. URL: https://doi.org/10.1261/rna.1471209, doi:10.1261/rna.1471209. This article has 49 citations and is from a domain leading peer-reviewed journal.

4. (rosenthal2015theemergingrole pages 5-6): Joshua J. C. Rosenthal. The emerging role of rna editing in plasticity. The Journal of Experimental Biology, 218:1812-1821, Jun 2015. URL: https://doi.org/10.1242/jeb.119065, doi:10.1242/jeb.119065. This article has 96 citations.

5. (palavicini2009anextradoublestranded pages 3-5): Juan Pablo Palavicini, Mary A. O'connell, and Joshua J.C. Rosenthal. An extra double-stranded rna binding domain confers high activity to a squid rna editing enzyme. RNA, 15 6:1208-18, Jun 2009. URL: https://doi.org/10.1261/rna.1471209, doi:10.1261/rna.1471209. This article has 49 citations and is from a domain leading peer-reviewed journal.

6. (palavicini2009anextradoublestranded pages 5-6): Juan Pablo Palavicini, Mary A. O'connell, and Joshua J.C. Rosenthal. An extra double-stranded rna binding domain confers high activity to a squid rna editing enzyme. RNA, 15 6:1208-18, Jun 2009. URL: https://doi.org/10.1261/rna.1471209, doi:10.1261/rna.1471209. This article has 49 citations and is from a domain leading peer-reviewed journal.

7. (OpenTargets Search: -ADAR2,ADARB1): Open Targets Query (-ADAR2,ADARB1, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (fisher2024structuralperspectiveson pages 5-6): Andrew J. Fisher and Peter A. Beal. Structural perspectives on adenosine to inosine rna editing by adars. Molecular Therapy - Nucleic Acids, 35:102284, Sep 2024. URL: https://doi.org/10.1016/j.omtn.2024.102284, doi:10.1016/j.omtn.2024.102284. This article has 22 citations.

9. (ashley2024adarfamilyproteins pages 7-8): Carolyn N. Ashley, Emmanuel Broni, and Whelton A. Miller. Adar family proteins: a structural review. Current Issues in Molecular Biology, 46:3919-3945, Apr 2024. URL: https://doi.org/10.3390/cimb46050243, doi:10.3390/cimb46050243. This article has 29 citations.

10. (ashley2024adarfamilyproteins pages 4-7): Carolyn N. Ashley, Emmanuel Broni, and Whelton A. Miller. Adar family proteins: a structural review. Current Issues in Molecular Biology, 46:3919-3945, Apr 2024. URL: https://doi.org/10.3390/cimb46050243, doi:10.3390/cimb46050243. This article has 29 citations.

11. (ashley2024adarfamilyproteins pages 8-9): Carolyn N. Ashley, Emmanuel Broni, and Whelton A. Miller. Adar family proteins: a structural review. Current Issues in Molecular Biology, 46:3919-3945, Apr 2024. URL: https://doi.org/10.3390/cimb46050243, doi:10.3390/cimb46050243. This article has 29 citations.

12. (budzko2023engineereddeaminasesas pages 2-3): Lucyna Budzko, Karolina Hoffa-Sobiech, Paulina Jackowiak, and Marek Figlerowicz. Engineered deaminases as a key component of dna and rna editing tools. Molecular Therapy - Nucleic Acids, 34:102062, Dec 2023. URL: https://doi.org/10.1016/j.omtn.2023.102062, doi:10.1016/j.omtn.2023.102062. This article has 16 citations.

13. (zhang2024rnaeditingenzymes pages 1-2): Dejiu Zhang, Lei Zhu, Yanyan Gao, Yin Wang, and Peifeng Li. Rna editing enzymes: structure, biological functions and applications. Cell & Bioscience, Mar 2024. URL: https://doi.org/10.1186/s13578-024-01216-6, doi:10.1186/s13578-024-01216-6. This article has 47 citations and is from a peer-reviewed journal.

14. (erdmann2021toprotectand pages 3-5): Emily A. Erdmann, Ananya Mahapatra, Priyanka Mukherjee, Boyoon Yang, and Heather A. Hundley. To protect and modify double-stranded rna – the critical roles of adars in development, immunity and oncogenesis. Critical Reviews in Biochemistry and Molecular Biology, 56:54-87, Dec 2021. URL: https://doi.org/10.1080/10409238.2020.1856768, doi:10.1080/10409238.2020.1856768. This article has 49 citations and is from a peer-reviewed journal.

15. (huebert2025frommetabolismto pages 20-22): David Huebert and Mani Larijani. From metabolism to mutation: the multifaceted roles of deaminases in biological systems. Unknown journal, Oct 2025. URL: https://doi.org/10.20944/preprints202510.0048.v1, doi:10.20944/preprints202510.0048.v1.

16. (yablonovitch2017theevolutionand pages 12-13): Arielle L. Yablonovitch, Patricia Deng, Dionna Jacobson, and Jin Billy Li. The evolution and adaptation of a-to-i rna editing. PLOS Genetics, 13:e1007064, Nov 2017. URL: https://doi.org/10.1371/journal.pgen.1007064, doi:10.1371/journal.pgen.1007064. This article has 142 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01